Segment Information and Geographical information

6 Months Ended

Jun. 30, 2011

Segment Information and Geographical information [Abstract]

Segment Information and Geographical information

Note 10—Segment Information and Geographical information

The Company has two reportable segments: Fibrocell Therapy and Agera. The Fibrocell Therapy segment specializes in the development and commercialization of autologous cellular therapies for soft tissue regeneration. The Agera segment maintains proprietary rights to a scientifically-based advanced line of skincare products. There is no intersegment revenue. The following table provides operating financial information for the continuing operations of the Company’s two reportable segments:

	Segment
	Fibrocell Therapy			Agera		Consolidated
Three Months Ended June 30, 2011
Total operating revenue	$	—		$	253,274	$	253,274
Depreciation and amortization expense		10,117			—		10,117
Segment income (loss) from continuing operations	$	(10,133,362	)	$	38,249	$	(10,095,113	)

	Segment
	Fibrocell Therapy			Agera		Consolidated
Six Months Ended June 30, 2011
Total operating revenue	$	—		$	461,910	$	461,910
Depreciation and amortization expense		12,590			—		12,590
Segment income (loss) from continuing operations	$	(27,205,372	)	$	59,661	$	(27,145,711	)
Supplemental information as of June 30, 2011
Total assets	$	9,830,330		$	689,282	$	10,519,612
Property and equipment, net		709,512			—		709,512
Intangible assets		6,340,656			—		6,340,656

An intercompany receivable as of June 30, 2011, of $1.0 million, due from the Agera segment to the Fibrocell Therapy segment, is eliminated in consolidation. This intercompany receivable is primarily due to the intercompany management fee charge to Agera by Fibrocell Technologies, Inc., as well as Agera’s working capital needs provided by Fibrocell Technologies, Inc., and has been excluded from total assets of the Fibrocell Therapy segment in the above table. There is no intersegment revenue. Total assets on the consolidated balance sheet at June 30, 2011 are approximately $10.5 million, which includes assets of discontinued operations of less than $0.1 million.

	Segment
	Fibrocell Therapy			Agera			Consolidated
Three Months Ended June 30, 2010
Total operating revenue	$	—		$	264,062		$	264,062
Depreciation and amortization expense		2,288			—			2,288
Segment income (loss) from continuing operations	$	(1,676,370	)	$	(21,393	)	$	(1,697,763	)

	Segment
	Fibrocell Therapy			Agera			Consolidated
Six Months Ended June 30, 2010
Total operating revenue	$	—		$	473,132		$	473,132
Depreciation and amortization expense		3,140			—			3,140
Segment income (loss) from continuing operations	$	(6,402,918	)	$	(10,488	)	$	(6,413,406	)
Supplemental information as of June 30, 2010
Total assets		6,858,898			641,244			7,500,142
Property and equipment, net		26,535			—			26,535
Intangible assets		6,340,656			—			6,340,656

An intercompany receivable as of June 30, 2010, of $1.0 million, due from the Agera segment to the Fibrocell Therapy segment, is eliminated in consolidation. This intercompany receivable is primarily due to the intercompany management fee charge to Agera by Fibrocell Technologies, as well as Agera’s working capital needs provided by Fibrocell Technologies, and has been excluded from total assets of the Fibrocell Therapy segment in the above table. There is no intersegment revenue. Total assets on the consolidated balance sheet at June 30, 2010 are approximately $7.5 million.

Geographical information concerning the Company’s revenue and fixed assets are as follows:

	Revenue
	Three months ended		Three months ended
	June 30, 2011		June 30, 2010
United States	$	47,350	$	61,654
United Kingdom		117,408		149,123
Other		88,516		53,285
Total	$	253,274	$	264,062

	Revenue
	Six months ended		Six months ended
	June 30, 2011		June 30, 2010
United States	$	95,473	$	121,848
United Kingdom		265,572		290,790
Other		100,865		60,494
Total	$	461,910	$	473,132

	Property, Plant & Equipment
	June 30, 2011		June 30, 2010
United States	$	709,512	$	21,589
Total	$	709,512	$	21,589

During the three months ended June 30, 2011, revenue from one foreign customer and one domestic customer represented 46% and 14% of consolidated revenue, respectively. During the three months ended June 30, 2010, revenue from one foreign customer and one domestic customer represented 75% and 16% of consolidated revenue, respectively.

During the six months ended June 30, 2011, revenue from one foreign customer and one domestic customer represented 57% and 15% of consolidated revenue, respectively. During the six months ended June 30, 2010, revenue from one foreign customer and one domestic customer represented 72% and 18% of consolidated revenue, respectively.

As of June 30, 2011 and December 31, 2010, one foreign customer represented 65% and 88%, respectively, of accounts receivable, net.